Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lysyl oxidase like 4 (LOXL4), a member of the secreted copper-dependent amine oxidases that contribute to the assemble and maintenance of the extracellular matrix (ECM), was found to be up-regulated or down-regulated in different cancer types, suggesting its paradoxical roles in cancer. The specific role of LOXL4 in
hepatocellular carcinoma
(
HCC
), however, is still yet to be defined. Twenty-eight pairs of
HCC
specimens were used for LOXL4 mRNA expression analysis. The mRNA expression in
HCC
cell lines was examined, and HepG2 was selected for LOXL4 small interfering RNA (siRNA) interference to investigate the biological function of LOXL4, LOXL4 immunohistochemical staining was performed using a tissue microarray containing 298
HCC
patients. The prognostic and diagnostic value of LOXL4 was evaluated using Cox regression and Kaplan-Meier analysis. LOXL4 mRNA or protein expression was significantly lower in
HCC
tissues than peritumoral tissues (LOXL4 mRNA expression, P = 0.018;
LOXL4 protein
expression, P < 0.001). Low LOXL4 expression was associated with lower overall survival (OS) rates and higher cumulative recurrence rates. Multivariate analysis indicated that LOXL4 was an independent prognostic indicator for OS and time to recurrence (TTR). Our results revealed that LOXL4 was down-regulated in
HCC
and correlated with aggressive tumors and a worse clinical outcome. LOXL4 may be a potential biomarker to identify the
HCC
patients with a higher risk of recurrence.
...
PMID:LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis. 2609 73